Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...

The number of reported measles cases in the United States has hit 1,288 in the first six months of this year, the most since ...

People with "young" brains -- brains aging more slowly than their actual age -- are much less likely to die or develop ...

Although ‘lean type 2 diabetes’ is not uncommon, clinicians must first exclude other causes including autoimmune, monogenic, ...

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...

In a recent panel conversation, healthcare and industry experts discussed where to find reliable guidance in a sea of ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...